Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.) Patents (Class 424/94.6)
  • Patent number: 11898203
    Abstract: Provided herein are methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: February 13, 2024
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Vikram Pattanayak, Karl Petri
  • Patent number: 11891635
    Abstract: A method for modifying double stranded DNA (dsDNA) employing an RNA guided DNA endonuclease to generate two double strand breaks in the dsDNA molecule to be modified, and replacement of the sequence positioned between the double strand breaks with a substitute DNA sequence using the non-homologous end joining (NHEJ) pathway, and corresponding kits and compositions for modifying double stranded DNA molecules.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 6, 2024
    Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
    Inventors: Ralf Kühn, Eric Danner
  • Patent number: 11865187
    Abstract: A composition comprising at least one AAV vector formulated for central nervous system delivery is described. The composition comprises at least one expression cassette which contains sequences encoding an anti-neoplastic immunoglobulin construct for delivery to the brain operably linked to expression control sequences therefor and a pharmaceutically acceptable carrier. The anti-neoplastic immunoglobulin construct may be an immunoglobulin modified to have decreased or no measurable affinity for neonatal Fc receptor (FcRn). Also provided are methods of using these constructs in preparing pharmaceutical compositions and uses thereof in anti-neoplastic regimens, particularly for primary and/or metastatic cancers of the brain.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: January 9, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, William Thomas Rothwell, Christian Hinderer
  • Patent number: 11820969
    Abstract: Provided herein are systems, compositions, and methods of introducing protective and/or loss-of-function variants of CCR5 and CCR2. Variants may be introduced using a CRISPR/Cas9-based nucleobase editor or other guide nucleotide sequence-programmable DNA binding protein domain-based fusion protein described herein. Further provided herein are compositions and methods of preventing and treating conditions related to HIV infection and progression as well as to AIDS.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: November 21, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: Juan Pablo Maianti, David R. Liu
  • Patent number: 11746340
    Abstract: The invention relates to improved alkaline phosphatases, pharmaceutical compositions comprising improved alkaline phosphatases and the use of improved alkaline phosphatases for preventing, treating or curing diseases.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: September 5, 2023
    Assignee: AM-PHARMA B.V.
    Inventors: Willem Raaben, Luigi Johannes Cornelius Jonk, Erik Jan Van Den Berg, Andrea Van Elsas, José Luis Millán
  • Patent number: 11701410
    Abstract: The invention relates to the use of deoxyribonuclease (DNase) enzyme for inhibiting progression and for prevention and treatment of neurodegeneration.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: July 18, 2023
    Assignee: CLS THERAPEUTICS LIMITED
    Inventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
  • Patent number: 11680092
    Abstract: The present invention relates to a novel cancer-associated biomarker and different applications and uses thereof. More specifically, the invention relates to a novel splice variant of CIP2A denoted as NOCIVA, as well as binding bodies such as probes, amplification primers, and antibodies specific for the same. Also provided are various methods for detecting and prognosing cancer on the basis of said splice variant, and a kit for use in said methods.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 20, 2023
    Assignee: TURUN YLIOPISTO
    Inventors: Eleonora Mäkelä, Jukka Westermarck
  • Patent number: 11654184
    Abstract: The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: May 23, 2023
    Assignee: Theriva Biologics, Inc.
    Inventors: Michael Kaleko, Christian Furlan Freguia, Sheila Connelly
  • Patent number: 11584777
    Abstract: A method for purification of a sulfatase using metal chelating chromatography without using tags such as His-tag, etc. is disclosed. An embodiment provides a method for purifying a sulfatase including the steps of: (a) providing a sulfatase-containing solution comprising one or a plurality of impurities; (b) performing a first chromatographic separation of the sulfatase-containing solution using a metal affinity chromatography resin; (c) performing a second chromatographic separation using a cation exchange chromatography resin; and (d) performing a final chromatographic separation using an anion exchange chromatography resin, wherein the impurities are removed thereby.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: February 21, 2023
    Assignee: GREEN CROSS CORPORATION
    Inventors: Denis Feshin, Byung Hyun Park, Yong Won Shin
  • Patent number: 11564978
    Abstract: Disclosed herein are methods for treating a subject with an alkaline phosphatase deficiency, further comprising monitoring additional analytes, e.g., calcium, parathyroid hormone and/or vitamin D, with treatment modifications as indicated by the levels, e.g., serum levels, of the additional analytes.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: January 31, 2023
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventor: Tatjana Odrljin
  • Patent number: 11541106
    Abstract: The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: January 3, 2023
    Assignee: Eligo Bioscience
    Inventors: Antoine Decrulle, Xavier Duportet
  • Patent number: 11530393
    Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: December 20, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: Dave Nichols
  • Patent number: 11530397
    Abstract: The present invention relates to polypeptides, nucleotides encoding the polypeptide, as well as methods of producing the polypeptides. The present invention also relates to detergent composition comprising polypeptides, a laundering method and the use of polypeptides.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: December 20, 2022
    Assignee: Novozymes A/S
    Inventors: Morten Gjermansen, Klaus Gori, Henrik Marcus Geertz-Hansen, Jesper Salomon, Mary Ann Stringer, Thomas Holberg Blicher, Nikolaj Spodsberg
  • Patent number: 11504418
    Abstract: Disclosed herein is an endotoxin-free asparaginase enzyme. Also disclosed are methods of using the disclosed enzyme to treat subjects with a disease treatable by depletion of asparagine. For example, the disclosed endotoxin-free asparaginase enzyme is useful in the treatment or the manufacture of a medicament for use in the treatment of acute lymphoblastic leukemia (ALL) in both adults and children, as well as other conditions where asparagine depletion is expected to have a useful effect.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: November 22, 2022
    Assignee: CROWPIERCE TECHNOLOGIES, LLC
    Inventors: George E. Pierce, Sidney A. Crow
  • Patent number: 11447757
    Abstract: The present disclosure relates to methods for using one or more polypeptides with phytase activity in grain processing, ethanol, and biofuel production.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: September 20, 2022
    Assignee: BASF ENZYMES LLC
    Inventors: Danielle Cusumano, Tony Newton, Arne I. Solbak
  • Patent number: 11434265
    Abstract: The present invention relates to chimeric neurotoxins with enhanced properties and their use in therapy.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: September 6, 2022
    Assignee: IPSEN BIOPHARM LIMITED
    Inventor: Sai Man Liu
  • Patent number: 11291637
    Abstract: The invention relates to methods of treating or preventing organophosphate poisoning in a subject in need thereof, comprising administering to the subject isoflurane, enflurane, halothane, sevoflurane, desflurane, xenon or argon in a therapeutically effective amount.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 5, 2022
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Jishnu K. S. Krishnan, Aryan M. Namboodiri, John R. Moffett, Peethambaran Arun, Narayanan Puthillathu, Ranjini Vengilote
  • Patent number: 11286469
    Abstract: The present disclosure provides compositions, methods and kits for the treatment of cancer. Particularly, the present disclosure provides synergistic compositions comprising at least one cytotoxic ribonuclease and at least one MAPK-pathway inhibitor.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: March 29, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Ronald T. Raines, Trish Hoang
  • Patent number: 11103526
    Abstract: PNPase inhibitors (such as 8-substituted guanine and/or 8-substituted guanosine) and/or PNPase purine nucleoside substrates (such as guanosine and/or inosine) can also be used in methods of treating SCD or reducing sickling of red blood cells (RBCs). Herein, 8-substituted guanine and/or 8-substituted guanosine compounds are used in methods to treat hypertension (such as systemic or pulmonary hypertension), stroke, diabetes, and/or patients in need of a diuretic. In addition, 8-substituted guanine and/or 8-substituted guanosine compounds are included in a beverage composition. Further, purine nucleoside phosphorylase (PNPase) inhibitors (such as 8-substituted guanine and/or 8-substituted guanosine) and/or PNPase purine nucleoside substrates (such as guanosine and/or inosine) can be used in methods of treating or reducing the risk of pulmonary hypertension (PH), such as PH associated with HIV or sickle cell disease (SCD).
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: August 31, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Edwin K. Jackson, Stevan P. Tofovic
  • Patent number: 11096950
    Abstract: The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: August 24, 2021
    Inventor: Barbara Brooke Jennings
  • Patent number: 11098296
    Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 24, 2021
    Assignees: The Trustees of Columbia University in the City of New York, University of Kentucky Research Foundation
    Inventors: Donald Landry, Chang-Guo Zhan
  • Patent number: 11059982
    Abstract: The aim of the present invention is to provide a fluid composition that can form a coating, said composition being characterized in that it contains, at least in a solvent medium, an effective amount of at least one natural virucide selected from among lauric acid, monolaurin, lactoferrin and essential oils having antiviral activity and/or one of the precursors thereof, said composition having a viscosity of 30 mPa·s to 40 Pa·s at room temperature and pressure.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: July 13, 2021
    Assignee: OBERTHUR FIDUCIAIRE SAS
    Inventor: Henri Rosset
  • Patent number: 10941186
    Abstract: The invention relates to expressing proteins in the axons of mammalian neurons. The invention provides nucleic acids that can be used to express a selected polypeptide in neuronal axons, viruses that can be used deliver nucleic acids of the invention into neuronal axons, as well as methods for doing so. Thus, the invention provides pharmaceutical compositions comprising viruses of the invention, as well as their use in methods of treating injured axons or conditions associated with aberrant axon growth or function.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: March 9, 2021
    Assignee: Cornell University
    Inventors: Samie R. Jaffrey, Ulrich Hengst
  • Patent number: 10934534
    Abstract: This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: March 2, 2021
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Erno Pungor, Charles Hague, Zhi Chen, Melita Dvorak-Ewell, Michel Claude Vellard, Vish Koppaka
  • Patent number: 10925930
    Abstract: The present invention provides a method for treating and/or ameliorating a disorder of the lower urinary tract, comprising administering a composition comprising a glucagon like peptide 2 (GLP-2) receptor agonist to a patient in need thereof in an amount sufficient to treat and/or ameliorate the disorder of the lower urinary tract.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 23, 2021
    Assignee: URIGEN N.A.
    Inventors: Christopher P. Meenan, C. Lowell Parsons, Daniel Vickery
  • Patent number: 10912845
    Abstract: The present invention relates to an improved method of providing photoreceptor function to a cell, for example for use in the treatment of retinal degeneration. The present invention also relates to compositions and kits, in particular for use in such methods.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: February 9, 2021
    Assignee: The University of Manchester
    Inventors: Robert Lucas, Paul Bishop, Jasmina Cehajic-Kapetanovic
  • Patent number: 10898548
    Abstract: Composition and methods are provided for the specific manipulation of protein tyrosine phosphatase (PTP) activity, including without limitation manipulation of protein tyrosine phosphatase receptor type gamma (PTPRG). The modulation of PTP activity can be performed in vitro or in vivo, and is useful for therapeutic and research purposes. In some embodiments, an effective dose of a PTP modulator is provided to an individual for preventing or treating disease involving dysregulated tyrosine kinase activity and/or signaling mechanisms involving tyrosine phosphorylation and/or tyrosine kinase activity. In other embodiments, a PTP modulator is utilized in the analysis and screening of phosphatase pathways in a cell.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: January 26, 2021
    Assignee: LEUVAS THERAPEUTICS
    Inventors: Carlo Laudanna, Lucia De Franceschi
  • Patent number: 10881736
    Abstract: The present disclosure provides biophotonic compositions, kits and their uses. In particular, the biophotonic compositions of the present disclosure are substantially resistant to leaching such that low amounts of chromophores present in the biophotonic composition leach out of the composition. The biophotonic compositions and their uses are useful for promoting repair of non-healing wounds.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: January 5, 2021
    Assignee: KLOX TECHNOLOGIES INC.
    Inventors: Nikolaos Loupis, Remigio Piergallini, Shipra Rastogi
  • Patent number: 10874719
    Abstract: The present invention provides a method of treating or preventing immunoinflammatory, vascular, thrombotic or ischemic disorders in a subject, the method comprises administering to the subject an agent which dissipates nucleotide phosphates or generates a product which stimulates adenosine receptors. The present invention also provides a method of treating or preventing immunoinflammatory, thrombotic or ischemic disorders in a subject by inhibiting leukocyte infiltration into a site which comprises administering to the subject an effective amount a described agent. Agents described for use in the methods of the invention include CD73, a fragment a mutant, or a modified form thereof.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: December 29, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: David J. Pinsky, Danica Petrovic-Djergovic
  • Patent number: 10864255
    Abstract: The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: December 15, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Gregory A. Grabowski, Hong Du
  • Patent number: 10858642
    Abstract: The present invention relates to immunogenic polypeptide fragments of a human Arginase protein. The fragments are in particular useful for the treatment or prevention of cancer.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: December 8, 2020
    Assignee: IO Biotech ApS
    Inventor: Mads Hald Andersen
  • Patent number: 10775597
    Abstract: An interferometric scattering microscope is adapted by performing spatial filtering of output light, which comprises both light scattered from a sample location and illuminating light reflected from the sample location, prior to detection of the output light. The spatial filtering passes the reflected illumination light but with a reduction in intensity that is greater within a predetermined numerical aperture than at larger numerical apertures. This enhances the imaging contrast for coherent illumination, particularly for objects that are weak scatterers.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: September 15, 2020
    Assignee: Oxford University Innovation Limited
    Inventors: Philipp Kukura, Alexander Weigel, Justin Benesch
  • Patent number: 10772940
    Abstract: The presently-disclosed subject matter includes isolated polypeptides that comprise a butyrylcholinestrase (BChE) polypeptide and a second polypeptide. The BChE polypeptide as well as the second polypeptide can be variants and/or fragments thereof. The presently-disclosed subject matter also includes a pharmaceutical composition that comprises the present isolated polypeptide and a suitable pharmaceutical carrier. Further still, methods are provided for treating cocaine-induced conditions, and comprise administering the isolated polypeptide and/or pharmaceutical compositions thereof to an individual.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: September 15, 2020
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Hsin-Hsiung Tai, Xiabin Chen, Liu Xue, Shurong Hou
  • Patent number: 10745677
    Abstract: Provided herein are systems, compositions, and methods of introducing protective and/or loss-of-function variants of CCR5 and CCR2. Variants may be introduced using a CRISPR/Cas9-based nucleobase editor or other guide nucleotide sequence-programmable DNA binding protein domain-based fusion protein described herein. Further provided herein are compositions and methods of preventing and treating conditions related to HIV infection and progression as well as to AIDS.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 18, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Juan Pablo Maianti, David R. Liu
  • Patent number: 10745664
    Abstract: The present invention is directed to novel methods comprising the isolation of viable fetal progenitor cells from organs of aborted fetus. The invention comprises the use of natural proteolytic, collagenolytic and fibrinolytic activity of autologous abortive placenta tissue extract.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 18, 2020
    Assignee: Reelabs Private Limited, a Company Incorporated Under Provisions of The Companies Act 1956
    Inventors: Abhijit Bopardikar, Rohit Kulkarni, Sunil Pophale, Andrii Kukharchuk, Oleksandr Kukharchuk, Padma Priya Anand Baskaran
  • Patent number: 10655099
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: May 19, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Patent number: 10640806
    Abstract: Methods and compositions to restore function to acidified T cells are provided. The methods comprise administering urease to the T cells. Compositions comprise urease.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: May 5, 2020
    Assignee: Helix BioPharma Corp.
    Inventors: Wah Yau Wong, Baomin Tian, Kim Gaspar, Marni Diane Uger, Sven Rohmann, Heman Lap Man Chao
  • Patent number: 10626387
    Abstract: The present invention discloses a lysin that is capable of killing Staphylococcus and the use thereof, belonging to the field of biological agents. The present invention discloses the amino acid sequence and the encoding gene sequence of the lysin. This lysin keeps active in a wide range of pH. It has lytic activity against Staphylococcus in pH 4-11. The recombinant protease constructed by the encoding gene can be solubly expressed in E. coli strain BL21 (DE3). The lysin can be used to effectively kill multiple species Staphylococcus in vitro, including methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant Staphylococcus aureus (MRSA) isolated in clinics. This lysin can be used as an antibiotic for the treatment of staphylococcal infections in vivo. This lysin is also able to rapidly lyse staphylococcal cell wall; as a result, intracellular substances such as ATP and DNA are released. Those released substances can be used to detect the type of Staphylococcus.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: April 21, 2020
    Assignee: Phagelux, Inc.
    Inventors: Hongping Wei, Hang Yang, Junping Yu
  • Patent number: 10563183
    Abstract: This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 18, 2020
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Erno Pungor, Charles Hague, Zhi Chen
  • Patent number: 10526593
    Abstract: The present invention discloses a composition for biomass hydrolysis. The components of the composition may be obtained by biological or synthetic means. Synthetically, the components of the composition of the present invention may be obtained by amino acid synthesis or may be procured commercially.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: January 7, 2020
    Assignees: International Centre For Genetic Engineering & Biotechnology, Department of Biotechnology Ministry of Science & Technology
    Inventors: Syed Shams Yazdani, Funso Emmanuel Ogunmolu
  • Patent number: 10407671
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: September 10, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Anthony Quinn, Alex J. Harvey
  • Patent number: 10344270
    Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 9, 2019
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Dave Nichols
  • Patent number: 10308920
    Abstract: The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds).
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: June 4, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: Uwe T. Bornscheuer, David Weiner, Tim Hitchman, Jonathan Lyon, Sirirung Wongsakul
  • Patent number: 10293032
    Abstract: Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 21, 2019
    Assignee: TAMIR BIOTECHNOLOGY, INC.
    Inventors: Luis Squiquera, Jamie Sulley
  • Patent number: 10286046
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 14, 2019
    Assignee: Seikagaku Corporation
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • Patent number: 10265355
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-1 that is isolated from the nature and can kill specifically Shigatoxin-producing type F18 E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12662BP), and a method for preventing and treating the infections of Shigatoxin-producing type F18 E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim
  • Patent number: 10196698
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer. In a specific embodiment, present inventors have developed and applied a new technology and associated computation methods enabling simultaneous genome-scale analysis of genetic (copy number) and epigenetic (total methylation (TM) and allele-specific methylation (ASM) alternation, This method, called MBD-SNP, features affinity enrichment or methylated genomic DNA fragments using a methyl-binding domain polypeptide.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: February 5, 2019
    Assignee: The Johns Hopkins University
    Inventors: Srinivasan Yegnasubramanian, G. Steven Bova, Martin Aryee, William B. Isaacs, William G. Nelson
  • Patent number: 10188705
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: January 29, 2019
    Assignees: Icahn School of Medicine at Mount Sinai, Genzyme Corporation
    Inventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
  • Patent number: 10160960
    Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 25, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald Landry, Chang-Guo Zhan
  • Patent number: RE47233
    Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fission protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: February 12, 2019
    Assignee: Vision Global Holdings Ltd.
    Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok, Yun Chung Leung